Efficacy and Safety Study of Bevacizumab Plus Chemotherapy in EGFR-TKI Resistant Non-Squamous Non-Small Cell Lung Cancer

NCT02139579 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Lung, Carcinoma

Interventions

DRUG: Bevacizumab

Sponsor

Sun Yat-sen University

Collaborators

[object Object]
[object Object]